The SME Misvik Biology Oy provides cell-based high-throughput-driven research services, cutting-edge imaging-based and plate-based high-throughput screening platforms as well as omics analysis services. Misvik has over the last five years developed laboratory technologies to run complex high content imaging-based drug screens, allowing for single cell resolution of drug response characteristics for personalized cancer care in rare cancers as well as regulatory safety testing of engineered nanomaterials. In 2015 when clinical development of the ex vivo therapy efficacy testing platform was initiated, Misvik was the first and only company in Europe developing the platform for solid cancers.

https://www.misvik.com/